From U Milan: Cost of Cystic Fibrosis "tend to increase progressively with age"

http://www.ncbi.nlm.nih.gov/pubmed/23397400

Adv Ther. 2013 Feb 7. [Epub ahead of print]

Cost of Cystic Fibrosis: Analysis of Treatment Costs in a Specialized Center in Northern Italy.

Colombo C, Daccò V, Alicandro G, Loi S, Mazzi S, Lucioni C, Ravasio R.

Source

Cystic Fibrosis Centre - Fondazione IRCCS, Ca' Granda, Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

Abstract

INTRODUCTION:

Advances in cystic fibrosis (CF) therapy have resulted in improved survival and increasing treatment burden and costs. The economic impact of current treatment strategies for CF is poorly defined.

METHODS:

The authors prospectively assessed direct medical costs (including hospitalizations, outpatient interventions, drugs, devices, dietetic products) in 165 consecutive CF patients (aged 5-39 years) seen between March and July 2009.

RESULTS:

The mean annual cost/patient increased with age and lung disease severity from <euro>4,164 in children aged ≤5 years to <euro>30,123 in patients aged >5 years with severe lung disease (forced expiratory volume in 1 second [FEV(1)] <40% of predicted). The increase in costs involved all items, with a progressive increase in cost attributed to hospitalizations.

CONCLUSION:

Treatment of CF is associated with relevant cost for the Italian National Healthcare Service. Costs of illness tend to increase progressively with age, suggesting that increasing economic resources should be allocated to the treatment of CF, given the increasing number of patients surviving into adulthood.